$KMPH Announces FDA Approval of AZSTARYS™
KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD
Corium, Inc. will lead the commercialization of AZSTARYS per the definitive collaboration and license agreement.
Corium expects to make AZSTARYS commercially available in the U.S. as early as the second half of 2021.
Under the License Agreement, KemPharm may be eligible for up to $468 million in regulatory and sales milestone payments, as well as tiered royalty payments, on a product-by-product basis for net sales, with potential percentages up to the mid-twenties for U.S. net sales, and up to the mid-single digits of net sales in each country outside of the U.S.
finance.yahoo.com/news/kempharm-announces-fda-approval-azstarys-043100312.html
Corium, Inc. will lead the commercialization of AZSTARYS per the definitive collaboration and license agreement.
Corium expects to make AZSTARYS commercially available in the U.S. as early as the second half of 2021.
Under the License Agreement, KemPharm may be eligible for up to $468 million in regulatory and sales milestone payments, as well as tiered royalty payments, on a product-by-product basis for net sales, with potential percentages up to the mid-twenties for U.S. net sales, and up to the mid-single digits of net sales in each country outside of the U.S.
finance.yahoo.com/news/kempharm-announces-fda-approval-azstarys-043100312.html
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.